ES2073398T3 - Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular. - Google Patents

Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular.

Info

Publication number
ES2073398T3
ES2073398T3 ES88121405T ES88121405T ES2073398T3 ES 2073398 T3 ES2073398 T3 ES 2073398T3 ES 88121405 T ES88121405 T ES 88121405T ES 88121405 T ES88121405 T ES 88121405T ES 2073398 T3 ES2073398 T3 ES 2073398T3
Authority
ES
Spain
Prior art keywords
inhibitors
malonico
cinamilideno
bencilideno
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88121405T
Other languages
English (en)
Inventor
Alexander Levitzki
Chaim Gilon
Michael Chorev
Aviv Gazit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL84937A external-priority patent/IL84937A/xx
Priority claimed from IL88354A external-priority patent/IL88354A0/xx
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES2073398T3 publication Critical patent/ES2073398T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring

Abstract

SE PROVEEN COMPOSICIONES FARMACEUTICAS CONTENIENDO SEGUN UN INGREDIENTE ACTIVO UN COMPUESTO DE FORMULA GENERAL (I) DESCRITA EN MEMORIA,DONDE R1 Y R2 SON CADA UNO E INDEPENDIENTEMENTE CN, CONH2 O COOH O SOLO UNO DE R1 Y R2 PUEDE SER - CSNH2 O, CUANDO R1 ES CN R2 PUEDE TAMBIEN SER EL GRUPO (I): SIENDO R3 HIDROGENO, CH3 U OH, R4, R5, R6, R7 SON CADA UNO INDEPENDIENTEMENTE H, OH, C1 -5 ALQUIL, C1 - 5 ALCOXI, NH2, CHO, HALOGENO, NO2 O COOH, O R4 Y R5 PUEDEN REPRESENTAR A LA VEZ UN GRUPO - O - CH2 - O -; ENTENDIENDO QUE: (A) CUANDO R4 Y R7 SON CADA UNO OH, R3, R5 Y R6 SON CADA UNO H Y UNO DE ENTRE R1 Y R2 ES CN, ENTONCES EL OTRO DE ENTRE R1 Y R2 NO PUEDE SER CONH2; Y (B) CUANDO R3 Y R7 SON CADA UNO H, R5 ES OH Y R4 Y R6 SON AMBOS H O AMBOS C1 - 5 ALQUIL, ENTONCES R1 ES CN Y R2 ES CN O EL GRUPO (II), O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ELLOS. TAMBIEN SE PROVEEN ALGUNOS NUEVOS COMPUESTOS DE LA FORMULA (I) CITADA. LAS COMPOSICIONES Y COMPUESTOS DE ACUERDO AL INVENTO SON EFICIENTES INHIBIDORESDE ENCIMAS DE TIROSINA PROTEICA Y SON UTILES PARA LA INHIBICION DE PROCESOS PROLIFERATIVOS EN CELULAS DE MAMIFEROS.FIG 1.
ES88121405T 1987-12-24 1988-12-21 Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular. Expired - Lifetime ES2073398T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL84937A IL84937A (en) 1987-12-24 1987-12-24 Pharmaceutical compositions comprising benzylidene- malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
IL88354A IL88354A0 (en) 1988-11-10 1988-11-10 Pharmaceutical compositions comprising benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells,certain such novel compounds and their preparation

Publications (1)

Publication Number Publication Date
ES2073398T3 true ES2073398T3 (es) 1995-08-16

Family

ID=26321754

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88121405T Expired - Lifetime ES2073398T3 (es) 1987-12-24 1988-12-21 Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular.

Country Status (8)

Country Link
EP (2) EP0322738B1 (es)
JP (2) JP2806954B2 (es)
AT (1) ATE120955T1 (es)
AU (1) AU632992B2 (es)
CA (1) CA1334826C (es)
DE (1) DE3853577T2 (es)
ES (1) ES2073398T3 (es)
NZ (1) NZ227436A (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618595B2 (en) * 1988-04-28 1992-01-02 Suntory Limited Derivative of caffeic acid and pharmaceutical composition containing the same
AU662480B2 (en) * 1990-04-16 1995-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
DE4230262A1 (de) * 1992-09-10 1994-03-17 Behringwerke Ag Substituierte Phenole, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von zellproliferationsbedingten Erkrankungen
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
GB9802522D0 (en) 1998-02-06 1998-04-01 Montford University De Hydroxylation activated prodrugs
DE69918950T2 (de) 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
JP2003531133A (ja) 2000-04-13 2003-10-21 エイチエスシー リサーチ アンド ディベロップメント リミテッド パートナーシップ 細胞増殖を調節する新規化合物
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
JP4425628B2 (ja) * 2001-07-23 2010-03-03 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法
US20050014690A1 (en) * 2001-10-11 2005-01-20 Chaim Roifman Styryl acrylonitrile compounds and their use to promote myelopoiesis
US7598419B2 (en) 2004-03-26 2009-10-06 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
UA101168C2 (ru) 2007-10-29 2013-03-11 Натко Фарма Лимитед 4-(тетразол-5-ил)хиназолиновые производные как противораковые средства
HRP20231572T1 (hr) 2014-07-03 2024-03-15 Silti Ag Postupci i pripravci za liječenje pretilosti, sprečavanje dobivanja na težini, promicanje gubitka težine, promicanje mršavljenja, ili liječenje ili prevenciju razvoja dijabetesa
CA3226004A1 (en) * 2018-10-04 2020-04-09 Hydro-Quebec Additives for electrolytes in li-ion batteries
AU2022332335A1 (en) 2021-08-25 2024-04-11 García Sada, Fernando Compositions and methods for preventing or reducing the risk of metabolic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522188A (en) * 1962-06-27 1970-07-28 Gaf Corp Use of alpha-alkyl (or alkenyl) benzylidene malononitriles as u.v. absorbers,and stabilized compositions and light filters containing same
AU500541B2 (en) * 1975-09-29 1979-05-24 Ici Australia Limited Substituted benzylidene malonitriles
US4064266A (en) * 1975-09-29 1977-12-20 Ici Australia Limited Compositions for killing internal parasites containing 3-tert-alkyl-4-hydroxy-5-halo-benzylidene-malonitriles
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4781750A (en) * 1985-08-27 1988-11-01 Rohm And Haas Company Herbicidally active enols
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
AU618595B2 (en) * 1988-04-28 1992-01-02 Suntory Limited Derivative of caffeic acid and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
JPH02138238A (ja) 1990-05-28
CA1334826C (en) 1995-03-21
DE3853577T2 (de) 1995-08-31
EP0614661A3 (en) 1994-11-02
ATE120955T1 (de) 1995-04-15
AU632992B2 (en) 1993-01-21
EP0322738A2 (en) 1989-07-05
DE3853577D1 (de) 1995-05-18
AU2736088A (en) 1989-06-29
EP0614661A2 (en) 1994-09-14
JP2806954B2 (ja) 1998-09-30
EP0322738A3 (en) 1991-05-08
EP0322738B1 (en) 1995-04-12
NZ227436A (en) 1992-10-28
JPH10279477A (ja) 1998-10-20

Similar Documents

Publication Publication Date Title
ES2073398T3 (es) Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular.
FI810250L (fi) Foerfarande foer framstaellning av nya terapeutiskt aktiva heterocykliska foereningar
ATE163412T1 (de) Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren
DE68925223D1 (de) 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-en-2-carbonsäure-Verbindungen
NO158017C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
ATE51618T1 (de) Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen.
ATE18196T1 (de) 1,4-acyloxynaphthalenderivate, diese enthaltende kompositionen, verfahren fuer ihre herstellung und zwischenprodukte dafuer.
ES2064361T3 (es) Nuevos compuestos.
ATE50248T1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
ATE62663T1 (de) Indan-derivate, verfahren zu ihrer herstellung und die erhaltenen zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
ES542393A0 (es) "4-(nitrofenil)-tetrahidropiridinas,procedimiento para su obtencion y su empleo como medicamento"
MA19434A1 (fr) Procede de preparation de nouvelles imidazo/i, 2-a/quinoleines et de leurs sels
ES428673A1 (es) Procedimiento para la obtencion de derivados de nitrobenzo-fenona sustituidos.
ES552486A0 (es) Un procedimiento para la obtencion de compuestos de 1-oxa-1-dertia cefalosporina.
GB1203430A (en) Heterocyclic spiro compounds
ES8707254A1 (es) Un procedimiento para preparar un derivado de imidazopiridazina
ES8506014A1 (es) Procedimiento para la preparacion de derivados de acridanona.
GB1327042A (en) Oxazole derivatives their preparation and pharmaceutical compositions containing the same
TH2663A (th) สารประกอบเฮเทอโรไซคลิค
ATE73801T1 (de) Heterocyclische oxophthalazinylessigsaeure.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 322738

Country of ref document: ES